Skip to content
Satellos Bioscience Logo

Satellos Biosciences: Presents Positive Preclinical Efficacy Data for SAT-3247

March 5, 2024

Satellos Bioscience Inc. announced today positive preclinical data showing SAT-3247 can improve skeletal muscle function in multiple mouse models of muscle degeneration.

Press release highlights:

  • Orally administered SAT-3247 demonstrates efficacy across three mouse models of muscle degeneration
  • Efficacy in muscle injury model demonstrates broad potential of SAT-3247

The preclinical data presented show the broad potential of SAT-3247 to improve skeletal muscle function as has been demonstrated in three mouse models of muscle degeneration: mdx model of Duchenne muscular dystrophy (DMD), FLExDUX4 model of facioscapulohumeral muscular dystrophy (FSHD), and a muscle injury model in wildtype mice. In all instances, treatment with SAT-3247 over a three-to-four-week period resulted in a statistically significant improvement in muscle force versus animals receiving placebo.

“These data bolster our confidence in developing SAT-3247 for the treatment of diseases and conditions, such as DMD and FSHD, that are characterized by muscle damage in the face of inadequate muscle fiber regeneration. We believe the muscle injury data further expand and broaden the potential for SAT-3247 into non-dystrophy disease indications as well as multiple forms of muscle injury or trauma in otherwise healthy individuals.”

“We continue on our development plan to advance SAT-3247 into first-in-human clinical trials mid-year.”

Frank Gleeson, Cofounder and CEO of Satellos

On March 6 at 12:30pm ET, at the 2024 MDA Clinical & Scientific Conference in Orlando, Phil Lambert, Ph.D., Chief Scientific Officer of Satellos will give an oral presentation, entitled, “SAT-3247: An Oral Small Molecule Inhibitor Targeting AAK1, a Critical Effector of Skeletal Muscle Regeneration.”

What is SAT-3247?

Satellos SAT-3247 is a small molecule designed to inhibit AAK1, a protein kinase member of the Notch pathway. The Company believes AAK1 inhibition, independent of dystrophin, has the capacity to regulate polarity to restore asymmetric muscle stem cell division, generate muscle progenitor cells, and enable muscle regeneration.

Defeat Duchenne Canada is pleased to be currently funding the work of Dr. Mike Rudnicki, who is the Director of the Regenerative Medicine Program at the Ottawa Research Institute and is also the Chief Scientific Officer of Satellos Bioscience Inc. 

Related Articles